The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

N. Tariot, Pierre; Lopera, Francisco; B. Langbaum, Jessica; G. Thomas, Ronald; Hendrix, Suzanne; S. Schneider, Lon; Ríos‐Romenets, Silvia; Giraldo, Margarita; Acosta‐Baena, Natalia; Tobón, Carlos; Ramos, Cláudia; Palacios–Espinosa, Alejandro; Cho, Yong‐Yeon; E. Ward, Michael; Clayton, David; Friesenhahn, Michael; Mackey, Howard; Honigberg, Lee; Sanabria Bohórquez, Sandra; Chen, Kewei; Walsh, Trisha; Langlois, Carolyn; M. Reiman, Eric; Prevention Initiative, Alzheimer's

doi:10.1016/j.trci.2018.02.002

Public

The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

Published in Alzheimer s & Dementia Translational Research & Clinical Interventions • Jan 1, 2018

Authors:

Pierre N. Tariot

Francisco Lopera

Jessica B. Langbaum

Abstract

INTRODUCTION: Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is, who have "...

Subject

PSEN1

Medicine

Disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!